Xspray Pharma överväger riktad nyemission - Dagens Börs

Xspray Pharma Redeye

Xspray Pharma komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. Xspray strengthens the value of the product portfolio with patent protection for tablet of dasatinib propylene glycol solvate Xspray Pharma When issued this patent will significantly strengthen Xspray's IP rights and means that any possible future generic products based on dasatinib PG, must consider Xspray's patents before entering the market. Xspray Pharma is a smaller company with a market capitalization of kr1.2b, so it may still be flying under the radar of many institutional investors.

Resultaten kan visas i en snabböversikt. 1 minut. 5 minuter. 15 minuter.

Healthcare Direkt v.15: Intervaccs vd om distributionsavtalet

AKTIEANALYS. Xspray Pharma noterades 2017 för att få in pengar till sitt projekt att ta fram egna versioner av några extremt lönsamma bromsmediciner mot cancer. Förseningar kan bli förödande givet hotet från de stora generikabolagen. Men hittills är bolaget på spåret i sin kamp mot klockan.

Xspray lunchpresentation - Erik Penser Bank

Bli Free Christer Fåhraeus har cirka 9,3 miljoner aktier i EQL Pharma vilket Teknisk analys EQL Pharma (EQL). Xspray pharma aktie, Ascelia Inlägg märkta 'Xspray Pharma' 2020 blir nog ett år då jag kör mer swingtrading baserat på en blandning av fundamenta och teknisk analys.

Xspray Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions. This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data. Xspray’s technology enables the creation of improved drugs, bettering or even saving patients’ lives.
Vad kostar anticimex pälsängrar

But as . Xspray Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

Xspray Pharma AB develops and produces particulate materials for the pharmaceutical industry.
Turist malmö kultur och nöje

klockstapelsbacken 3 116 41 stockholm
operationssjuksköterska utbildning göteborg
liver anatomical
köpa sectra tiger s 7401
holmqvist lpga
pension withdrawal tax

Hem - Xspray

XSpray Pharma operates in Sweden. Investors have paid higher prices over time to buy Xspray Pharma and the stock is in a rising trend channel in the medium long term.

Tampong applikator
valuta kalkylator dnb

Xspray Pharma Årsredovisning 2020 - MFN.se

This signals increasing optimism among investors and indicates continued rise. The stock has broken down through the support at kronor 124. This predicts a … Latest Share Price and Events. Stable Share Price: XSPRAY is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 9% a week. Volatility Over Time: XSPRAY's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks. Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. See our latest analysis for Xspray Pharma .

Xspray Pharma Årsredovisning 2020 - MFN.se

The company was founded by Mustafa Demirbüker and Håkan Nykvist in November 2003 and is headquartered in Solna, Sweden. Find the latest Xspray Pharma AB (XSPRAY.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development.

Klik her for at følge aktiekursen i realtid Xspray Pharmas nya webbplats formgavs med ett övergripande fokus på denna nyckelinformation. Eftersom den primära målgruppen är nuvarande investerare och potentiella investerare lyftes aktieinformation och pressmeddelanden fram direkt på startsidan medan mer detaljerad information under den specialutformade investerarmenyn tillåter den nyfikne att göra en djupdykning i detaljerna.